Influence of subclinical hypothyroid dysfunction on the level of cardiovascular risk in patients with rheumatoid arthritis using selenium
Objective: To study the effect of subclinical hypothyroid dysfunction (CGTD) to the level of cardiovascular risk in patients with rheumatoid arthritis (RA) consumed selenium. Material and methods. The study included 72 patients with a diagnosis of RA in combination with SGTD. Patients by random sampling were divided into two groups-PC. In group I (37 people), patients were included, which for 6 months of observation, except for basic therapy, obtained the drug sodium selenite; In group II, patients were included (35 people) who received the mill-dial treatment of RA. The level of total cholesterol (TCS), triglycerides (TG), cholesterol of high density lipoproteins (CS LHD), cholesterol of low density lipoprotein (CS LLD), cholesterol of very low density lipoprotein (CS LVLD), non-cholesterol of high density lipoprotein (non-LHD) before and after treatment. Cardiovascular (SS) risk was calculated using the Score scale, the Framingham scale (FSH), on the Reynolds scale (RSH) and the PROCAM scale before and after treatment. Research results. When studying cardiovascular risk in patients with RA with SGTD, selenium has been established for 6 months, it has been established that during the entire experiment, there is a decrease in the indicators of TCS, CS LHD, CS LLD, CS LVLD, non-CS-LHD, scale Score, Framingem scale, Reynolds scale and the PROCAM scale, which were evaluated, compared with patients receiving standard treatment of RA. Conclusion. Treatment of patients with RA with concomitant SGTD according to a complex scheme with the inclusion of a sodium selenite preparation can improve the lipid spectrum, reduce the level of CV risk, which is important in reducing mortality from CV complications in RA patients with SGTD.